Chabiotech Co.,Ltd. (KOSDAQ: 085660)

Market Cap	894.27B
Revenue (ttm)	974.80B
Net Income (ttm)	-22.48B
Shares Out	56.31M
EPS (ttm)	-499.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	165,682
Open	16,130
Previous Close	15,990
Day's Range	15,850 - 16,500
52-Week Range	13,510 - 23,100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Chabiotech Co.,Ltd.

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Ophthalmic Goods
• Founded: 2002
• Employees: 271
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2023, Chabiotech Co.,Ltd.'s revenue was 953.95 billion, an increase of 12.95% compared to the previous year's 844.58 billion. Losses were -8.43 billion, -82.27% less than in 2022.